INDP
Indaptus Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Indaptus Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Largest filed tie
0
filed ties
—
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No changes.
No changes.
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Annual filing, covered
10-K parsed · Mar 17 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 17 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Indaptus Therapeutics, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Indaptus Therapeutics, Inc..
Tall tick = annual report · Source: EDGAR
—
| Manager | Value | % base | |
|---|---|---|---|
| HRT Financial | $618,000 | 53.52% | new |
| Geodeindex-like | $169,410 | 14.67% | +109.09% |
| Jane Street | $161,433 | 13.98% | new |
| Vanguardindex-like | $100,956 | 8.74% | new |
| Vanguard Fiduciary Trustindex-like | $41,901 | 3.63% | new |
| Manager | Value | % base | |
|---|---|---|---|
| HRT Financial | $618,000 | 53.52% | new |
| Geodeindex-like | $169,410 | 14.67% | +109.09% |
| Jane Street | $161,433 | 13.98% | new |
| Vanguardindex-like | $100,956 | 8.74% | new |
| Vanguard Fiduciary Trustindex-like | $41,901 | 3.63% | new |
Indaptus Therapeutics, Inc.
3.26
+0.02 · +0.52%
Expected move
No implied move.